HENWOOD GERALDINE 4
4 · Recro Pharma, Inc. · Filed Jan 20, 2021
Insider Transaction Report
Form 4
HENWOOD GERALDINE
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2021-01-18+5,000→ 206,467 total - Tax Payment
Common Stock
2021-01-18$3.03/sh−6,816$20,652→ 199,651 total - Exercise/Conversion
Restricted Stock Units
2021-01-18−5,000→ 0 total→ Common Stock (5,000 underlying)
Holdings
- 50,000(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]Represents 2,240 shares of common stock from the January 18, 2017 grant of restricted stock units to the reporting person and 4,576 shares of common stock from the January 18, 2019 grant of restricted stock units to the reporting person withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
- [F3]On January 18, 2017, the reporting person was granted 20,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.